Renal sympathetic nerve activation via α2-adrenergic receptors in chronic kidney disease progression

Hee Seong Jang, Jinu Kim, Babu J Padanilam

Research output: Contribution to journalReview article

Abstract

Chronic kidney disease (CKD) is increasing worldwide without an effective therapeutic strategy. Sympathetic nerve activation is implicated in CKD progression, as well as cardiovascular dysfunction. Renal denervation is beneficial for controlling blood pressure (BP) and improving renal function through reduction of sympathetic nerve activity in patients with resistant hypertension and CKD. Sympathetic neurotransmitter norepinephrine (NE) via adrenergic receptor (AR) signaling has been implicated in tissue homeostasis and various disease progressions, including CKD. Increased plasma NE level is a predictor of survival and the incidence of cardiovascular events in patients with end-stage renal disease, as well as future renal injury in subjects with normal BP and renal function. Our recent data demonstrate that NE derived from renal nerves causes renal inflammation and fibrosis progression through alpha-2 adrenergic receptors (α2-AR) in renal fibrosis models independent of BP. Sympathetic nerve activation-associated molecular mechanisms and signals seem to be critical for the development and progression of CKD, but the exact role of sympathetic nerve activation in CKD progression remains undefined. This review explores the current knowledge of NE-α2-AR signaling in renal diseases and offers prospective views on developing therapeutic strategies targeting NE-AR signaling in CKD progression.

Original languageEnglish (US)
Pages (from-to)6-14
Number of pages9
JournalKidney Research and Clinical Practice
Volume38
Issue number1
DOIs
StatePublished - Mar 1 2019

Fingerprint

Chronic Renal Insufficiency
Adrenergic Receptors
Disease Progression
Kidney
Norepinephrine
Blood Pressure
Fibrosis
Adrenergic alpha-2 Receptors
Denervation
Chronic Kidney Failure
Neurotransmitter Agents
Homeostasis
Hypertension
Inflammation
Survival
Incidence
Wounds and Injuries
Therapeutics

Keywords

  • Denervation
  • Fibrosis
  • Inflammation
  • Norepinephrine
  • Reperfusion injury

ASJC Scopus subject areas

  • Nephrology
  • Urology

Cite this

Renal sympathetic nerve activation via α2-adrenergic receptors in chronic kidney disease progression. / Jang, Hee Seong; Kim, Jinu; Padanilam, Babu J.

In: Kidney Research and Clinical Practice, Vol. 38, No. 1, 01.03.2019, p. 6-14.

Research output: Contribution to journalReview article

@article{55fb09fa88c046ab869d0ca193e195ee,
title = "Renal sympathetic nerve activation via α2-adrenergic receptors in chronic kidney disease progression",
abstract = "Chronic kidney disease (CKD) is increasing worldwide without an effective therapeutic strategy. Sympathetic nerve activation is implicated in CKD progression, as well as cardiovascular dysfunction. Renal denervation is beneficial for controlling blood pressure (BP) and improving renal function through reduction of sympathetic nerve activity in patients with resistant hypertension and CKD. Sympathetic neurotransmitter norepinephrine (NE) via adrenergic receptor (AR) signaling has been implicated in tissue homeostasis and various disease progressions, including CKD. Increased plasma NE level is a predictor of survival and the incidence of cardiovascular events in patients with end-stage renal disease, as well as future renal injury in subjects with normal BP and renal function. Our recent data demonstrate that NE derived from renal nerves causes renal inflammation and fibrosis progression through alpha-2 adrenergic receptors (α2-AR) in renal fibrosis models independent of BP. Sympathetic nerve activation-associated molecular mechanisms and signals seem to be critical for the development and progression of CKD, but the exact role of sympathetic nerve activation in CKD progression remains undefined. This review explores the current knowledge of NE-α2-AR signaling in renal diseases and offers prospective views on developing therapeutic strategies targeting NE-AR signaling in CKD progression.",
keywords = "Denervation, Fibrosis, Inflammation, Norepinephrine, Reperfusion injury",
author = "Jang, {Hee Seong} and Jinu Kim and Padanilam, {Babu J}",
year = "2019",
month = "3",
day = "1",
doi = "10.23876/j.krcp.18.0143",
language = "English (US)",
volume = "38",
pages = "6--14",
journal = "Kidney Research and Clinical Practice",
issn = "2211-9132",
publisher = "Elsevier Korea",
number = "1",

}

TY - JOUR

T1 - Renal sympathetic nerve activation via α2-adrenergic receptors in chronic kidney disease progression

AU - Jang, Hee Seong

AU - Kim, Jinu

AU - Padanilam, Babu J

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Chronic kidney disease (CKD) is increasing worldwide without an effective therapeutic strategy. Sympathetic nerve activation is implicated in CKD progression, as well as cardiovascular dysfunction. Renal denervation is beneficial for controlling blood pressure (BP) and improving renal function through reduction of sympathetic nerve activity in patients with resistant hypertension and CKD. Sympathetic neurotransmitter norepinephrine (NE) via adrenergic receptor (AR) signaling has been implicated in tissue homeostasis and various disease progressions, including CKD. Increased plasma NE level is a predictor of survival and the incidence of cardiovascular events in patients with end-stage renal disease, as well as future renal injury in subjects with normal BP and renal function. Our recent data demonstrate that NE derived from renal nerves causes renal inflammation and fibrosis progression through alpha-2 adrenergic receptors (α2-AR) in renal fibrosis models independent of BP. Sympathetic nerve activation-associated molecular mechanisms and signals seem to be critical for the development and progression of CKD, but the exact role of sympathetic nerve activation in CKD progression remains undefined. This review explores the current knowledge of NE-α2-AR signaling in renal diseases and offers prospective views on developing therapeutic strategies targeting NE-AR signaling in CKD progression.

AB - Chronic kidney disease (CKD) is increasing worldwide without an effective therapeutic strategy. Sympathetic nerve activation is implicated in CKD progression, as well as cardiovascular dysfunction. Renal denervation is beneficial for controlling blood pressure (BP) and improving renal function through reduction of sympathetic nerve activity in patients with resistant hypertension and CKD. Sympathetic neurotransmitter norepinephrine (NE) via adrenergic receptor (AR) signaling has been implicated in tissue homeostasis and various disease progressions, including CKD. Increased plasma NE level is a predictor of survival and the incidence of cardiovascular events in patients with end-stage renal disease, as well as future renal injury in subjects with normal BP and renal function. Our recent data demonstrate that NE derived from renal nerves causes renal inflammation and fibrosis progression through alpha-2 adrenergic receptors (α2-AR) in renal fibrosis models independent of BP. Sympathetic nerve activation-associated molecular mechanisms and signals seem to be critical for the development and progression of CKD, but the exact role of sympathetic nerve activation in CKD progression remains undefined. This review explores the current knowledge of NE-α2-AR signaling in renal diseases and offers prospective views on developing therapeutic strategies targeting NE-AR signaling in CKD progression.

KW - Denervation

KW - Fibrosis

KW - Inflammation

KW - Norepinephrine

KW - Reperfusion injury

UR - http://www.scopus.com/inward/record.url?scp=85067401055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067401055&partnerID=8YFLogxK

U2 - 10.23876/j.krcp.18.0143

DO - 10.23876/j.krcp.18.0143

M3 - Review article

VL - 38

SP - 6

EP - 14

JO - Kidney Research and Clinical Practice

JF - Kidney Research and Clinical Practice

SN - 2211-9132

IS - 1

ER -